// App-Quantinova.ai

409 : Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies

Researchers

Presenter

  • Philip J Mease

Principal Investigators

  • Atul Deodhar

  • Maxime Dougados

  • Maureen Dubreuil

  • Marina Magrey

  • Helena Marzo-Ortega

  • Martin Rudwaleit

  • Christine de la Loge

  • Alicia Ellis

  • Carmen Fleurinck

  • Marga Oortgiesen

  • Vanessa Taieb

  • Lianne Gensler

Medical Centers

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

  • Oregon Health & Science University, Portland, OR, USA, Portland, OR

  • Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France

  • Department of Medicine, Boston University School of Medicine, Boston, MA

  • Case Western Reserve University and University Hospitals, Cleveland, OH

  • NIHR, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, United Kingdom

  • University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Brussels, Belgium, Oosterzele, Belgium

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Colombes, France

  • Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Franciso, California, United States

Locations

  • United States

  • France

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03928704

  • NCT03928743

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved